Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Enesi Pharma Achieves Key Milestone in Development of Thermostable Solid-dose Live Vaccines against Measles and Rubella

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies.

Enese Pharma today announced it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. The project, which started in October 2019, received funding from the Bill & Melinda Gates Foundation.

The project established important proof-of-concept for ImplaVax®-enabled unit solid-dose presentations of both vaccines, demonstrating that each was thermally stable at temperatures of 40°C for three days and at 25°C for at least one month, and met key criteria for retained activity.  Further longer-term stability studies are underway, and the Company is planning the immunogenicity studies needed to determine the next development steps to progress the novel vaccine formulations towards clinical trials.

Measles and Rubella vaccines are typically maintained in a lyophilized (freeze-dried) form that requires reconstitution in solution prior to injection using a needle and syringe. Once reconstituted, however, the vaccines exhibit very poor thermal stability and rapidly lose effectiveness if not refrigerated. This is an important consideration in low- and middle-income countries (LMIC) where cold-chain issues and access to target populations for vaccinations can be challenging.

By eliminating the need for reconstitution and improving thermal stability, ImplaVax®-enabled Measles and Rubella vaccines could improve the cost-effectiveness of supply and robustness of vaccine deployment and delivery in these regions. Additionally, ImplaVax®-enabled Measles and Rubella vaccines may provide further benefits that improve vaccination uptake and coverage based on needle-free delivery of a unit dose minimizing vaccine wastage, elimination of needlestick, and cross-contamination hazards and waste and requirement for minimal training.

David Hipkiss, Enesi Pharma CEO, commented: “We are extremely grateful for the support we have received from the Bill & Melinda Gates Foundation to undertake this project. It is very exciting to see the results emerging from this and the many other collaborations we initiated over the past few years with leading partners, including those announced recently in pandemic flu and in significant animal health indications. These results are establishing preclinical proof-of-concept for ImplaVax®-enabled solid dose forms of vaccines based on many of the major current formats in use today. As we successfully achieve key milestones in these collaborations, we are building a firm foundation of evidence supporting our belief that our ImplaVax® solid-dose technology could be a potentially transformational approach to improving vaccination against significant health threats globally.”

 

 

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine